Table 2 Summary of clinical trials investigating the combination of ADCs and chemotherapy
From: The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Target | NCT number | Other names | Drug | Partner drugs | Partner drug category (target) | Phase | Start | Treatment setting | Efficacy |
|---|---|---|---|---|---|---|---|---|---|
HER2 | NCT01702558 [19] | TRAXHER2 | T-DM1 | Capecitabine | CT | I | 2012 | mBC, mGC | Negative |
NCT02073916 [20] | STELA | T-DM1 | Lapatinib + Abraxane | EGFR/HER2 TKI + CT | I | 2013 | mBC | Positive | |
NCT02073487 [21] | TEAL | T-DM1 | Lapatinib + Abraxane | EGFR/HER2 TKI + CT | II | 2014 | Neoadjuvant, BC | Positive | |
NCT02562378 [22] | THELMA | T-DM1 | Non-pegylated Liposomal Doxorubicin | CT | I | 2015 | mBC | Negative | |
NCT03190967 [23] | NA | T-DM1 | TMZ | CT | I/II | 2017 | mBC | Terminated | |
NCT04686305 [24] | DL03 | T-DXd | Durvalumab and Cisplatin | IO + CT | Ib | 2020 | mNSCLC | NA | |
Durvalumab and Carboplatin | IO + CT | NA | |||||||
Durvalumab and Pemetrexed | IO + CT | NA | |||||||
Durvalumab and Cisplatin | IO + CT | NA | |||||||
Durvalumab and Carboplatin | IO + CT | NA | |||||||
Durvalumab and Pemetrexed | IO + CT | NA | |||||||
Durvalumab | IO | NA | |||||||
TROP2 | NCT05687266 (recruiting) | AVANZAR | Datopotamab deruxtecan | Durvalumab + Carboplatin | IO + CT | III | 2022 | mNSCLC | NA |
Nectin-4 | NCT03288545 [25] | EV-103 | Enfortumab vedotin | Pembrolizumab | IO | I/II | 2017 | mUC | Positive |
Cisplatin | CT | NA | |||||||
Carboplatin | CT | NA | |||||||
Gemcitabine | CT | NA | |||||||
Platinum + Pembrolizumab | IO + CT | NA | |||||||
Pembrolizumab | IO | MIBC | NA | ||||||
TF | NCT03485209 [26] | InnovaTV 207 | Tisotumab Vedotin | Pembrolizumab + (Carboplatin or DDP) | IO + CT | II | 2018 | Advanced solid tumors | NA |
Pembrolizumab | IO | NA | |||||||
EGFR | NCT02573324 [27] | Intellance1 | Depatuxizumab Mafodotin | TMZ and Radiation | CT + Radiation | III | 2015 | GBM | Positive |
NaPi2b | NCT04907968 (active, not recruiting) | UPGRADE | Upifitamab Rilsodotin | Carboplatin | CT | I | 2021 | High grade serous ovarian cancer | Terminated |
FRα | NCT02606305 [28] | NA | Mirvetuximab Soravtansine | Bevacizumab | Anti-VEGF mAb | Ib/II | 2022 | High-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers | Positive |
Carboplatin | CT | NA | |||||||
Pegylated Liposomal Doxorubicin | CT | NA | |||||||
Pembrolizumab | IO | NA | |||||||
Bevacizumab + Carboplatin | CT + Anti-VEGF mAb | NA |